Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20763906 | 0.77 | PDK2 (0.36) | TDP1CA2TSHRLMNA | |
| SCHEMBL14216812 | 0.76 | ALDH1A1 (0.36) | MAOBMAOAKCNH2TSHR | |
| SCHEMBL31410709 | 0.74 | — | — | |
| SCHEMBL22402480 | 0.74 | ESR1 (0.44) | — | |
| SCHEMBL20763624 | 0.72 | PTGS1 (0.40) | TSHRMEN1LMNAKMT2A | |
| SCHEMBL24209554 | 0.72 | LOXL2 (0.41) | MAOBCA2CA1CA5ACA9 | |
| SCHEMBL17625640 | 0.71 | TSHR (0.37) | TSHR | |
| SCHEMBL17625666 | 0.70 | DGAT1 (0.33) | — | |
| SCHEMBL17625664 | 0.69 | MAOA (0.39) | MAOBMAOAKCNH2MEN1KMT2A | |
| SCHEMBL17625650 | 0.69 | CES1 (0.35) | TDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11913944-B2 | Photoaffinity probes | PROMEGA CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220317138-A1 | METHODS FOR DETERMINING THE CONCENTRATION OF A CARBAPENEM ANTIBIOTIC IN A BIOLOGICAL SAMPLE | Université de Liège (BE) | 2022-10-06 | — | — | US | disclosed |
| US-20200340982-A1 | PHOTOAFFINITY PROBES | PROMEGA CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170362221-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-21 | — | — | US | disclosed |
| WO-2017136689-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | ACADEMIA SINICA (TW) | 2017-08-10 | — | — | WO | disclosed |
| EP-2721038-B1 | ALKYLAMINO BODIPY DYES AS SELECTIVE FLUORESCENT PROBES FOR PROTEINS AND MOUSE EMBRYONIC STEM CELLS | NAT UNIV SINGAPORE (SG) | 2017-07-26 | — | — | EP | disclosed |
| US-9689021-B2 | Method for measuring beta-lactam antibiotics | Université de Liège (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9550978-B2 | Isolation and functional identification of cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160349268-A1 | STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES | CAPROTEC BIOANALYTICS GMBH (DE) | 2016-12-01 | — | — | US | disclosed |
| EP-2913674-A1 | Stepwise assembled capture compounds comprising a cleavable function and method for isolating and/or characterizing biomolecules or biomolecule fragments, in particular proteins or protein fragments, of complex mixtures | Caprotec Bioanalytics GmbH (DE) | 2015-09-02 | — | — | EP | disclosed |
| US-20130295636-A1 | Isolation and Functional Identification of Cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| WO-2008054481-A2 | IMPROVED INACTIVATED INFLUENZA VIRUS COMPOSITIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080072794-A1 | Reactive Silicon Suboxide Flakes | HOPPE HOLGER | 2008-03-27 | — | — | US | disclosed |
| US-7176297-B2 | Photoactivatable silane compounds and methods for their synthesis and use | AFFYMETRIX, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | MAOB 4316/4885MAOA 4481/4885ACHE 4005/4885 |
| US-20160349268-A1 | STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES | FGB, CPB1, FURIN | MAOB 1889/4885MAOA 3759/4885ACHE 3492/4885 |
| US-20170362221-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | GLS, GLS2, GLUL | MAOB 2761/4885MAOA 3264/4885ACHE 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.